Bone marrow disease in rhabdomyosarcoma visualized by 2-[ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography.
Pia KröningSebastian BergMartin T FreitagReineke A SchootAlexandra FischerAlexander PuzikT FeuchtingerCharlotte NiemeyerPhilipp Tobias MeyerMarkus UhlSimone HettmerPublished in: Pediatric radiology (2024)
Bone marrow metastases-noted in 6% of patients with rhabdomyosarcoma-have been linked to very poor outcomes. Bilateral bone marrow sampling from iliac crests has been the gold standard for bone marrow examination in rhabdomyosarcoma, but sampling errors due to patchy bone marrow involvement may limit its sensitivity. Here, we report the case of a 6-year-old boy with embryonal rhabdomyosarcoma of the skull base and multiple 2-[ 18 F]fluoro-2-deoxy-D-glucose (2-[ 18 F]FDG)-avid bone marrow metastases visualized by positron emission tomography and computed tomography (2-[ 18 F]FDG PET/CT). His bone marrow aspirates were tumor-free. This case illustrates the diagnostic value of 2-[ 18 F]FDG PET/CT in the detection of bone marrow metastases in rhabdomyosarcoma patients, which may re-shape the definition of bone marrow disease and, ultimately, alter disease staging and risk stratification.
Keyphrases
- bone marrow
- positron emission tomography
- computed tomography
- mesenchymal stem cells
- pet ct
- magnetic resonance imaging
- end stage renal disease
- chronic kidney disease
- type diabetes
- contrast enhanced
- ejection fraction
- lymph node
- quality improvement
- peritoneal dialysis
- dual energy
- patient safety
- weight loss
- patient reported outcomes
- glycemic control
- real time pcr